Clinical Trial 22259

(Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of GT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Disease Site: Other Digestive Organ, Small Intestine, Stomach

PI: Druta, Mihaela

Clinical Trial 22294

A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

Disease Site: Soft Tissue

PI: Mullinax, John

Clinical Trial 22713

Disease Site: Any Site

PI: Soliman, Hatem

Clinical Trial 23098

A Phase IB Clinical Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab with or without chemotherapy in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Disease Site: Eye and Orbit, Lip, Oral Cavity and Pharynx

PI: Kirtane, Kedar

Clinical Trial 23200

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer

Disease Site: Lung

PI: Yu, Hsiang-Hsuan (Michael)

Clinical Trial 20578

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Disease Site: Lymphoma, Non-Hodgkin's Lymphoma

PI: Locke, Frederick

Clinical Trial 21074

A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFRMutant cfDNA in Plasma After Initiation of Osimertinib

Disease Site: Lung

PI: Pellini, Bruna

Clinical Trial 20733

Disease Site: Myeloid and Monocytic Leukemia

PI: Vargas Madueno, Fernando

Clinical Trial 21220

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Disease Site: Larynx, Lip, Oral Cavity and Pharynx

PI: Biachi de Castria, Tiago

Clinical Trial 21525

A Feasibility Study of Genomically Guided Radiation Dose Personalization in the Management of Locally Advanced Non-Small Cell Lung Cancer

Disease Site: Lung

PI: Dilling, Thomas

Clinical Trial 21690

A Phase 1b, Single Arm Study of CG0070 after Transurethral Resection in Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)

Disease Site: Urinary Bladder, Other Urinary

PI: Li, Roger

Clinical Trial 21778

An Open-Label Phase 1A/1B Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Disease Site: Myeloid and Monocytic Leukemia

PI: Sallman, David